Company alerts ❯
-
Stealth BioTherapeuticsand Pharmanovia partner for commercialisation of elamipretide. Read more
Stealth BioTherapeutics (NAS: MITO)
LT 2419419 of 521Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.Longevity pillar- Treatment
- Prevention
Longevity domain:- Longevity drugs
- Neuropharma
- Discovery platforms
Longevity target: Aging Driver, Aging Disease -
Adiso Therapeuticsannounces the completion of a phase 1b for the treatment of moderately-to-severely active ulcerative colitis. Read more
ADISO therapeutics
LT 201212 of 521ADISO therapeutics creates novel therapies for inflammatory diseases. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, ADISO therapeutics are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action.Longevity pillar- Prevention
- Treatment
Longevity domain:- Longevity immunity
Longevity target: Aging Driver -
Seal Rock Therapeuticsannounces out-licensing agreement with GENFIT. Read more
Seal Rock therapeutics
LT 2394394 of 521Seal Rock therapeutics discovery and development efforts are focused on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that when activated under a variety of stressful disease conditions can drive severe pathological outcomes including fibrosis and inflammation. The company’s lead clinical indication is non-alcoholic steatohepatitis (NASH), while its expanding R&D pipeline offers additional compelling high unmet need disease opportunities, including alcoholic hepatitis (AH), chronic kidney disease, heart failure and Parkinson’s diseaseLongevity pillar- Treatment
- Prevention
Longevity domain:- Longevity immunity
- Discovery platforms
Longevity target: Aging Disease, Aging Driver -
Humacytegrows human blood vessels and sends them to wounded Ukraine soldiers. Read more
Humacyte Inc.
LT 2205205 of 521Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.Longevity pillar- Renewal
- Treatment
Longevity domain:- Regeneration
Longevity target: Aging Disease -
Athersysfiles to sell 5.685mn shares of common stock for holders. Read more
Athersys (NAS: ATHX)
LT 204848 of 521Athersys are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell therapy platform, for disease indications in areas of neurological, inflammatory & immune, and cardiovascular disease areas, as well as other critical care indications where there is substantial unmet medical need due to the limitations in standard of care.Longevity pillar- Treatment
- Renewal
Longevity domain:- Regeneration
Longevity target: Aging Driver, Aging Disease -
Heartseedbags $14mn Series D. Read more
Heartseed
LT 2202202 of 521Heartseed produce a large amount of ventricular type cardiomyocytes from iPS cells. Heartseeds original purification method (patented in major countries), which eliminates undifferentiated cells and non-cardiomyocytes, minimizes the risk of teratoma formation and arrhythmia.Longevity pillar- Renewal
- Treatment
Longevity domain:- Regeneration
Longevity target: Aging Disease